03/24/2026 | Press release | Distributed by Public on 03/24/2026 14:08
As filed with the Securities and Exchange Commission on March 24, 2026
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER THE
SECURITIES ACT OF 1933
BIOAGE LABS, INC.
(Exact name of Registrant as specified in its charter)
|
Delaware |
47-4721157 |
|
(State or other jurisdiction of |
(I.R.S. Employer |
5885 Hollis Street, Suite 370
Emeryville, California 94608
(510) 806-1445
(Address, including zip code, and telephone number, including area code, of Registrant's principal executive offices)
2024 Equity Incentive Plan
2024 Employee Stock Purchase Plan
(Full title of the plans)
Kristen Fortney, Ph.D.
Chief Executive Officer and President
BioAge Labs, Inc.
5885 Hollis Street, Suite 370
Emeryville, California 94608
(510) 806-1445
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Please send copies of all communications to:
Matthew Rossiter, Esq.
Robert A. Freedman, Esq.
Julia Forbess, Esq.
Fenwick & West LLP
One Front Street
33rd Floor
San Francisco, California 94111
(415) 875-2300
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definition of "large accelerated filer", "accelerated filer", "smaller reporting company", and "emerging growth company" in Rule 12b-2 of the Exchange Act.
|
Large accelerated filer |
☐ |
Accelerated filer |
☐ |
|
|
Non-accelerated filer |
☒ |
Smaller reporting company |
☒ |
|
|
Emerging growth company |
☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
Registration of Additional Shares
Pursuant to General Instruction E
BioAge Labs, Inc. (the "Registrant") is filing this Registration Statement with the Securities and Exchange Commission (the "Commission") to register (a) 1,869,345 additional shares of the Registrant's common stock available for issuance under the Registrant's 2024 Equity Incentive Plan (the "2024 EIP") pursuant to the provision of the 2024 EIP providing for an annual 5% automatic increase in the number of shares reserved for issuance under the 2024 EIP, and (b) 373,869 additional shares of the Registrant's common stock available for issuance under the Registrant's 2024 Employee Stock Purchase Plan (the "2024 ESPP") pursuant to the provision of the 2024 ESPP providing for an annual 1% automatic increase in the number of shares reserved for issuance under the 2024 ESPP.
In accordance with General Instruction E of Form S-8, and only with respect to the common stock issuable under the 2024 EIP and 2024 ESPP, this Registration Statement hereby incorporates by reference the contents of the Registrant's Registration Statements on Form S-8 filed with the Commission on September 26, 2024 (Registration No. 333-282352) and March 20, 2025 (Registration No. 333-285980) to the extent not superseded hereby.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3. Incorporation of Documents by Reference
The following documents filed by the Registrant with the Commission pursuant to the Securities Act and the Securities Exchange Act of 1934, as amended (the "Exchange Act") are incorporated herein by reference:
All documents and definitive proxy or information statements filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the filing of this Registration Statement and prior to the filing
of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing such documents, except as to documents or information deemed to have been furnished and not filed in accordance with the rules of the Commission. Unless expressly incorporated into this Registration Statement, a report deemed to be furnished but not filed on Form 8-K prior or subsequent to the date hereof shall not be incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement.
Item 5. Interests of Named Experts and Counsel
As of the date of this registration statement, individuals and entities associated with Fenwick & West LLP beneficially own an aggregate of 4,380 shares of the Registrant's common stock.
Item 8. Exhibits
The following exhibits are filed herewith:
|
Exhibit |
Incorporated by Reference |
|||||
|
Number |
Exhibit Description |
Form |
File No. |
Exhibit |
Filing Date |
Filed Herewith |
|
3.1 |
10-Q |
001-42279 |
3.1 |
11/7/2024 |
||
|
3.2 |
10-Q |
001-42279 |
3.2 |
11/7/2024 |
||
|
4.1 |
S-1 |
333-281901 |
4.1 |
09/03/2024 |
||
|
5.1 |
X |
|||||
|
23.1 |
X |
|||||
|
23.2 |
X |
|||||
|
24.1 |
Power of Attorney (included on the signature page to this Registration Statement) |
X |
||||
|
99.1 |
2024 Equity Incentive Plan, and forms of award agreements thereunder |
10-K |
001-42279 |
10.2 |
03/20/2025 |
|
|
99.2 |
2024 Employee Stock Purchase Plan, and forms of award agreements thereunder |
S-1/A |
333-281901 |
10.4 |
09/18/2024 |
|
|
107 |
X |
|||||
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Emeryville, State of California, on this 24th day of March, 2026.
|
BIOAGE LABS, INC. |
||
|
By: |
/s/ Kristen Fortney, Ph.D. |
|
|
Kristen Fortney, Ph.D. |
||
|
Chief Executive Officer and President |
||
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Kristen Fortney, Ph.D. and Dov Goldstein, M.D., and each of them, as his or her true and lawful attorney-in-fact and agent with full power of substitution, for him or her in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons on behalf of the Registrant in the capacities and on the date indicated.
|
Name |
Title |
Date |
|
/s/ Kristen Fortney |
Chief Executive Officer, President and Director |
March 24, 2026 |
|
Kristen Fortney, Ph.D. |
(Principal Executive Officer) |
|
|
/s/ Dov Goldstein |
Chief Financial Officer |
March 24, 2026 |
|
Dov Goldstein, M.D. |
(Principal Financial Officer) |
|
|
/s/ Shane Barton |
Senior Vice President of Finance |
March 24, 2026 |
|
Shane Barton |
(Principal Accounting Officer) |
|
|
/s/ Jean-Pierre Garnier |
Chair of the Board of Directors |
March 24, 2026 |
|
Jean-Pierre Garnier, Ph.D. |
||
|
/s/ Michael Davidson |
Director |
March 24, 2026 |
|
Michael Davidson, M.D. |
||
|
/s/ Patrick Enright |
Director |
March 24, 2026 |
|
Patrick Enright |
||
|
/s/ James Healy |
Director |
March 24, 2026 |
|
James Healy, M.D., Ph.D. |
||
|
/s/ Rekha Hemrajani |
Director |
March 24, 2026 |
|
Rekha Hemrajani |
|
Name |
Title |
Date |
|
/s/ Eric Morgen |
Director |
March 24, 2026 |
|
Eric Morgen, M.D. |
||
|
/s/ Vijay Pande |
Director |
March 24, 2026 |
|
Vijay Pande, Ph.D. |